Oxford University

image for article on ovarian cancer prevention vaccine

Scientists in the U.K. developing world’s first vaccine to prevent ovarian cancer

By / / Good News For Humankind

OvarianVax, in development at the University of Oxford, has just received up to £600,000 from Cancer Research U.K. to pursue the world’s first vaccine designed to prevent ovarian cancer before it begins. The idea is to train the immune system to recognize over 100 proteins found on early-stage ovarian cancer cells, then destroy those cells before they can spread. For women carrying BRCA gene mutations, who currently face the wrenching choice of preventive surgery that ends fertility and triggers early menopause, a vaccine could transform what’s possible. It’s still early days, with lab work and clinical trials ahead, but the project signals a real shift in cancer research: moving from treatment toward prevention, and giving high-risk women better options worldwide.

A medical professional drawing blood from a patient's arm for an article about blood tests for dementia, for article on dementia blood test

U.K. launches blood tests for dementia in landmark five-year trial

By / / Good News For Humankind

Dementia blood tests are now being offered at more than 50 memory clinics across the U.K., in a landmark five-year trial aiming to transform how the disease is detected. Led by researchers at Oxford and University College London, the study will screen approximately 5,000 volunteers for protein biomarkers linked to Alzheimer’s and other forms of dementia. Currently, around one in three people with dementia in England has never received a formal diagnosis, and painful, slow pathways mean some patients wait up to four years for results. Earlier detection could connect patients to newer treatments that work best in the disease’s earliest stages.

Mushrooms, for article on psilocybin public opinion

Nearly 9 in 10 Americans now think using psilocybin is ‘morally positive,’ in dramatic shift in public opinion

By / / Good News For Humankind

Supervised psilocybin therapy just got a remarkable vote of confidence: in a new peer-reviewed survey of 795 U.S. adults, 91% of liberals and 86% of conservatives called its use for psychiatric treatment morally acceptable. That’s the kind of bipartisan agreement you almost never see anymore. Researchers from Oxford, Yale, Johns Hopkins, and Granada also found that strong majorities approved of psilocybin to enhance well-being in healthy people, not just to treat illness. The authors suggest compassion-based values help explain the consensus across political lines. As more states move toward legal, supervised psilocybin services, this quiet agreement among Americans hints at a broader, more humane shift in how societies might soon approach mental health.